In focus · trending topic

MIN-101 extension phase data

2 stories · following the connections

Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia

By Nasdaq OMXJun 22, 2017, 12:30 PM UTC

Minerva Neurosciences Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in Schizophrenia

By Nasdaq OMXOct 26, 2016, 12:30 PM UTC